| [1] |
Ulici V, Hart J. Chordoma[J]. Arch Pathol Lab Med, 2021, 146(3): 386-395.
|
| [2] |
Lee SH, Kwok KY, Wong SM, et al. Chordoma at the skull base, spine, and sacrum: A pictorial essay[J]. J Clin Imaging Sci, 2022, 12: 44.
|
| [3] |
Barber SM, Sadrameli SS, Lee JJ, et al. Chordoma-Current Understanding and Modern Treatment Paradigms[J]. J Clin Med, 2021, 10(5): 1054.
|
| [4] |
Mekouar M, Fahir O, Bouktib Y, et al. Clival Chordoma Presenting with Ophthalmoplegia and Frontal Headache: A Radioclinical Case Report[J]. Sch J Med Case Rep, 2025, 13(5): 1223-1226.
|
| [5] |
Bosman EM, Keizer ME, Aalst J van, et al. Spontaneous Shrinking and Growing Skull Base Chordoma[J]. J Neurol Surg Rep, 2025, 86(2): e107-e111.
|
| [6] |
江波，陈应明. 颅底脊索瘤的MR影像研究(论动态增强扫描的意义)[J]. 中华放射学杂志，2000，34(2)：22-24.
|
| [7] |
Martucci M, Russo R, Schimperna F, et al. Magnetic Resonance Imaging of Primary Adult Brain Tumors: State of the Art and Future Perspectives[J]. Biomedicines, 2023, 11(2): 364.
|
| [8] |
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8)：1231-1251.
|
| [9] |
Lee U, Lee RJ, Fahim DK. Prognostic factors and survival outcome in patients with chordoma in the United States; a population-based analysis[J]. World Neurosurg, 2017, 104: 346-355.
|
| [10] |
Batista KMP, Reyes KYA, Lopez FP, et al. Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity[J]. Współczesna Onkologia, 2017, 21(4): 267-273.
|
| [11] |
Prather KY, Shi HH, Mckinney KA, et al. Chronic cerebrospinal fluid rhinorrhea as an initial presentation of chordoma: illustrative case[J]. J Neurosurg Case Lessons, 2023, 5(14): CASE2347.
|
| [12] |
中国医疗保健国际交流促进会颅底外科学分会，欧美同学会医师协会颅底外科分会，中国医疗保健国际交流促进会神经外科分会. 颅底脊索瘤多学科诊疗专家共识[J]. 中华神经外科杂志，2023，39(5)：433-439.
|
| [13] |
Sekhon P, Rao NP, Patnaik U, et al. Clival Chordoma and its Management: A Case Report Highlighting a Multidisciplinary Approach to Achieve Optimal Outcomes[J]. DY Patil J Health Sci, 2024, 12(4): 168-172.
|
| [14] |
Youssef A, Morsi H, Bazak R, et al. Endoscopic endonasal approach for skull base chordoma[J]. Egypt J Otolaryngol, 2024, 40(1): 45.
|
| [15] |
Soffer JM, Ulloa R, Chen S, et al. A comparison of endoscopic endonasal versus open approaches for skull base chordoma: a comprehensive National Cancer Database analysis[J]. Neurosurg Focus, 2024, 56(5): E5.
|
| [16] |
王跃龙，吴安华，屈延，等. 复杂难治性颅底肿瘤的精准治疗进展[J]. 临床神经外科杂志，2025，22(1)：99-105.
|
| [17] |
郭一丁，赵本琦，张培海，等. 增强现实技术在颅底肿瘤和脑血管病手术中的应用[J]. 中国现代神经疾病杂志，2025，25(3)：215-224.
|
| [18] |
朱思鹏，霍续磊，吴震. 颅底脊索瘤综合治疗研究进展[J]. 中华神经外科杂志，2021, 37(11)：3811-3815.
|
| [19] |
Potter GM, Siripurappu R, Herwadkar A, et al. Skull Base Chordoma and Chondrosarcoma: Neuroradiologist's Guide to Diagnosis, Surgical Management, and Proton Beam Therapy[J]. Radiographics, 2024, 44(10): e240036.
|
| [20] |
Gendreau JL, Hameed NUF, Jimenez A, et al. Fractionated Radiotherapy After Gross Total Resection of Clival Chordoma: A Systematic Review of Survival Outcomes[J]. Neurosurgery, 2023, 93(2): 257-266.
|
| [21] |
Bin-Alamer O, Mallela AN, Palmisciano P, et al. Adjuvant stereotactic radiosurgery with or without postoperative fractionated radiation therapy in adults with skull base chordomas: a systematic review[J]. Neurosurg Focus, 2022, 53(5): E5.
|
| [22] |
Gao J, Jin J, Huang R, et al. RAB3B dictates mTORC1/S6 signaling in chordoma and predicts response to mTORC1-targeted therapy[J]. Adv Sci, 2025, 12(19): 2415384.
|
| [23] |
Meng T, Jin J, Jiang C, et al. Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review[J]. Front Oncol, 2019, 9: 30.
|
| [24] |
Lefler DS, Elliott A, Jiang W, et al. Pansarcoma analysis of cyclin-dependent kinase and cyclin outlier gene expression highlights CDK7 as a potential therapeutic target in chordoma[J]. JCO Precis Oncol, 2025, 9: e2500149.
|
| [25] |
Bompas E, Le Cesne A, Tresch-Bruneel E, et al. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)[J]. Ann Oncol, 2015, 26(10): 2168-2173.
|
| [26] |
Gounder MM, Rosen E, Parikh AR, et al. Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma[J]. J Clin Oncol, 2024, 42(16 suppl): 11522-11522.
|
| [27] |
Wu H, Li X, Zhang B, et al. Single-cell sequencing reveals VEGFR as a potential target for CAR-T cell therapy in chordoma[J]. Br J Cancer, 2024, 130(10): 1609-1620.
|
| [28] |
DeMaria PJ, Bilusic M, Park DM, et al. Randomized, double-blind, placebo-controlled phase II study of yeast-brachyury vaccine (G1-6301) in combination with standard-of-care radiotherapy in locally advanced, unresectable chordoma[J]. Oncologist, 2021, 26(5): e847-e858.
|
| [29] |
Brown N, Kuo C, Nguyen O, et al. SURG-07 Clival chordoma: A comprehensive meta-analysis of operative margins, progression free survival, and overall survival[J]. Neuro Oncol, 2023, 25(Supplement 5): 262.
|
| [30] |
Bakker SH, Jacobs WCH, Pondaag W, et al. Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival[J]. Eur Spine J, 2018, 27(12): 3043-3058.
|